WEBULL
News
IPSEY
35.41
NaN%
--
Weekly Report: what happened at IPSEY last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at IPSEY last week (1222-1226)?
Weekly Report · 12/29/2025 10:09
Weekly Report: what happened at IPSEY last week (1215-1219)?
Weekly Report · 12/22/2025 10:09
Simcere Pharma Licenses SIM0613 To Ipsen
NASDAQ · 12/22/2025 05:25
Weekly Report: what happened at IPSEY last week (1208-1212)?
Weekly Report · 12/15/2025 10:15
Weekly Report: what happened at IPSEY last week (1201-1205)?
Weekly Report · 12/08/2025 10:14
Weekly Report: what happened at IPSEY last week (1124-1128)?
Weekly Report · 12/01/2025 10:10
Weekly Report: what happened at IPSEY last week (1117-1121)?
Weekly Report · 11/24/2025 10:15
Weekly Report: what happened at IPSEY last week (1110-1114)?
Weekly Report · 11/17/2025 10:14
Weekly Report: what happened at IPSEY last week (1103-1107)?
Weekly Report · 11/10/2025 10:12
Weekly Report: what happened at IPSEY last week (1027-1031)?
Weekly Report · 11/03/2025 10:13
Weekly Report: what happened at IPSEY last week (1020-1024)?
Weekly Report · 10/27/2025 10:15
What To Expect From Gilead In Q3 2025
Seeking Alpha · 10/24/2025 14:56
Ipsen S.A. reports Q3 results; upgrades FY outlook
Seeking Alpha · 10/22/2025 07:09
Here are the major earnings before the open Wednesday
Seeking Alpha · 10/21/2025 22:00
Weekly Report: what happened at IPSEY last week (1013-1017)?
Weekly Report · 10/20/2025 10:12
Weekly Report: what happened at IPSEY last week (1006-1010)?
Weekly Report · 10/13/2025 10:15
Weekly Report: what happened at IPSEY last week (0929-1003)?
Weekly Report · 10/06/2025 10:12
Weekly Report: what happened at IPSEY last week (0922-0926)?
Weekly Report · 09/29/2025 10:12
Weekly Report: what happened at IPSEY last week (0915-0919)?
Weekly Report · 09/22/2025 10:13
More
Webull provides a variety of real-time IPSEY stock news. You can receive the latest news about Ipsen Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPSEY
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.